Session Details

[O]Picornaviridae 2

Mon. Nov 2, 2026 10:45 AM - 11:57 AM JST
Mon. Nov 2, 2026 1:45 AM - 2:57 AM UTC
Room 4 (3F Room 302)
Chair: Kyosuke Kobayashi (Immunity Control Unit, Research Center for Infectious Disease Medical Sciences, Tokyo Metropolitan Institute of Medical Science )
   Noriyo Nagata (Department of Infectious Disease Pathology, National Institute of Infectious Diseases, Japan Institute for Health Security)

[O1-4-6]Development of an intranasal vaccine against enterovirus D68 using virus-like particles

*Kotaro Taniguchi1,2, Yuta Kunishima2,3, Kota Senpuku1,2, Toshiro Hirai1,2,4,5, Taiki Ito2,4,5, Yasuo Yoshioka1,2,3,4,5 (1. Laboratory of Nano-design for Innovative Drug Development, School of Pharmaceutical Sciences, The University of Osaka, 2. Vaccine Creation Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Research Institute for Microbial Diseases, The University of Osaka, 3. The Research Foundation for Microbial Diseases of Osaka University, 4. Institute for Open and Transdisciplinary Research Initiatives, The University of Osaka, 5. Center for Advanced Modalities and DDS, The University of Osaka)

[O1-4-7]Antiviral Potential of Boreal Forest Biomass and Nordic Berries Against Enteroviruses and Coronavirus

*Varpu Seija Marjomaeki1 (1. University of Jyvaeskylae, Department of Biological and Environmental Science / Nanoscience center, FI-40500 Finland)

[O1-4-8]A cell-based biosensor for monitoring Parechovirus 3C protease activity: a versatile platform for antiviral compound screening

*Masahiko Takahashi1, Manami Takahashi1, Hirotaka Takahashi2, Kentaro Uemura3, Narumi Tetsuo4, Takayuki Abe1 (1. Division of Virology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, 2. Proteo-Science Center, Ehime University, 3. Center for Infectious Disease Education and Research, Osaka University, 4. Department of Applied Chemistry and Biochemical Engineering, Faculty of Engineering, Shizuoka University)

[O1-4-9]Ipriflavone inhibits Human Rhinovirus A16 infection

*Mitsuhisa Nariyama1, Kazuma Okada1,2, Kentaro Uemura1,2,3, Junki Hirano1,2,3, Chikako Ono1,2,3, Shuhei Taguwa1,2,3, Yoshiharu Matsuura1,2,3 (1. Laboratory of Virus Control, Center for Infectious Disease Education and Research (CiDER), The University of Osaka, 2. Laboratory of Virus Control, Research Institute for Microbial Diseases (RIMD), The University of Osaka, 3. Center for Advanced Modalities and DDS (CAMaD), The University of Osaka)

[O1-4-10]Short-course treatment with the hepato-selective dihydroquinolizinone HS83128 prevents hepatitis A following oral HAV challenge in mice

*Ichiro Misumi1, Jason K. Whitmire1,2,3, Timothy Block4,5, Stanley M. Lemon2,3,6, Yanming Du4,5, You Li7 (1. Dept. of Genetics, University of North Carolina at Chapel Hill, NC, USA, 2. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC, USA, 3. Dept. of Microbiology & Immunology, University of North Carolina at Chapel Hill, NC, USA, 4. Baruch S. Blumberg Institute, PA, USA, 5. Harlingene Life Sciences, PA, USA, 6. Dept. of Medicine, University of North Carolina at Chapel Hill, NC, USA, 7. Dept. of Pediatrics, University of North Carolina at Chapel Hill, NC, USA)

[O1-4-11]Establishment of a method for producing recombinant coxsackie virus using the CPER method

*Akira Ota1, Nobutaka Shirasaki2, Tomokazu Tamura3, Taku Matsushita2, Keisuke Maezono1, Hiroaki Kariwa1, Shintaro Kobayashi1,4,5,6 (1. Laboratory of Public Health, Department of Preventive Veterinary Medicine, Faculty of Veterinary Medicine, Hokkaido University, 2. Division of Environmental Engineering, Faculty of Engineering, Hokkaido University, 3. Department of Virology, Faculty of Medical Sciences, Kyushu University, 4. International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, 5. Institute of Vaccine Research and Development, Hokkaido University, 6. Institute for One Health Research Center, Hokkaido University)